Short Wave Pharma

Short Wave Pharma Sign Clinical Trial Agreement with Sheba Research Fund & Sheba Center for Eating Disorders to Study Psilocybin Treatment for Anorexia

Biopharmaceutical company Short Wave Pharma Inc. has announced a signed Clinical Trial Agreement with the Sheba Fund for Health Services and Research. Dr. Eitan

August 15, 2022

Short Wave Pharma

Short Wave Pharma Sign Clinical Trial Agreement with Sheba Research Fund & Sheba Center for Eating Disorders to Study Psilocybin Treatment for Anorexia

Choose Ketamine Complete Capital Raise to Expand Technology Platform

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Suggestions

Short Wave Pharma

Short Wave Pharma Sign Clinical Trial Agreement with Sheba Research Fund & Sheba Center for Eating Disorders to Study Psilocybin Treatment for Anorexia

Choose Ketamine Complete Capital Raise to Expand Technology Platform

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment